APA (7th ed.) Citation

Behr, J., Bendstrup, E., Crestani, B., Günther, A., Olschewski, H., Sköld, C. M., . . . Albera, C. (2016). Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: A randomised, double-blind, placebo-controlled, phase 2 trial. The lancet. Respiratory medicine, 4(6), . https://doi.org/10.1016/S2213-2600(16)30044-3

Chicago Style (17th ed.) Citation

Behr, Jürgen, et al. "Safety and Tolerability of Acetylcysteine and Pirfenidone Combination Therapy in Idiopathic Pulmonary Fibrosis: A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." The Lancet. Respiratory Medicine 4, no. 6 (2016). https://doi.org/10.1016/S2213-2600(16)30044-3.

MLA (9th ed.) Citation

Behr, Jürgen, et al. "Safety and Tolerability of Acetylcysteine and Pirfenidone Combination Therapy in Idiopathic Pulmonary Fibrosis: A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial." The Lancet. Respiratory Medicine, vol. 4, no. 6, 2016, https://doi.org/10.1016/S2213-2600(16)30044-3.